CRBU Q4 2022 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+44.3% YoY

Gross Profit

-$22M-597.1% margin

Operating Income

-$31M-828.2% margin

Net Income

-$27M-731.0% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$27M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$374M

Total Liabilities

$73M

Stockholders' Equity

$301M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+44.3%
Gross Profit	-$22M	$2M	-1064.3%
Operating Income	-$31M	-$20M	-49.9%
Net Income	-$27M	-$18M	-46.1%

Geographic Segments

UNITED STATES

$4M96%

Non-US

$150,0004%